EU/3/20/2381: Orphan designation for the treatment of progressive supranuclear palsy

(S)-N-(5-(4-(1-(benzo[d][1,3]dioxol-5-yl)ethyl)piperazin-1-yl)-1,3,4-thiadiazol-2-yl)acetamide, hydrochloride salt


On 9 December 2020, orphan designation EU/3/20/2381 was granted by the European Commission to Granzer Regulatory Consulting & Services, Germany, for (S)-N-(5-(4-(1-(benzo[d][1,3]dioxol-5-yl)ethyl)piperazin-1-yl)-1,3,4-thiadiazol-2-yl)acetamide, hydrochloride salt (also known as ASN90) for the treatment of progressive supranuclear palsy.

Key facts

Active substance
(S)-N-(5-(4-(1-(benzo[d][1,3]dioxol-5-yl)ethyl)piperazin-1-yl)-1,3,4-thiadiazol-2-yl)acetamide, hydrochloride salt
Intended use
Treatment of progressive supranuclear palsy
Orphan designation status
EU designation number
Date of designation

Ferrer Internacional S.A.
Gran Via De Carles III 94
08028 Barcelona

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

June 2023The sponsorship was transferred from Granzer Regulatory Consulting & Services, Germany, to Ferrer Internacional S.A., Spain in June 2023.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating